Table 4.
Activity of ertapenem in ESBL and non-ESBL producing Escherichia coli and Klebsiella pneumoniae isolates resistant to amoxicillin/clavulanate, piperacillin/tazobactam, and levofloxacin collected in the SMART study (2011-2015).
| Microorganisms | ESBL | Antimicrobial | % of resistant isolates | Ertapenem | ||
|---|---|---|---|---|---|---|
| Susceptible No. (%) | Intermediate No. (%) | Resistant No. (%) | ||||
| Escherichia coli | Negative | AMC | 11.4 | 297 (99.7) | 1 (0.3) | |
| Positive | 20.3 | 50 (100) | ||||
| Negative | P/T | 6.5 | 169 (99.4) | 1 (0.6) | ||
| Positive | 22.0 | 51 (99.4) | 1 (1.9) | 2 (3.7) | ||
| Negative | LVX | 21.8 | 571 (99.8) | 1 (0.2) | ||
| Positive | 69.5 | 170 (99.4) | 1 (0.6) | |||
| Klebsiella pneumoniae | Negative | AUG | 8.8 | 38 (86.4) | 2 (4.5) | 4 (9.1) |
| BLEE | 49.3 | 24 (64.9) | 2 (5.4) | 11 (29.7) | ||
| Negative | P/T | 7.2 | 27 (75.0) | 6 (16.7) | 3 (8.3) | |
| BLEE | 62.7 | 28 (59.6) | 2 (4.3) | 17 (36.2) | ||
| Negative | LVX | 4.8 | 19 (79.2) | 1 (4.2) | 4 (16.7) | |
| BLEE | 6.8 | 37 (72.5) | 1 (2.0) | 13 (25.5) | ||
ETP: ertapenem; AUG: amoxicillinclavulanate; P/T: piperacillin-tazobactam; LVX: levofloxacin.